The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1757-Patient Cohort

The AndroCoV Clinical Scoring for COVID-19 Diagnosis was developed as a sensitive, costless, and feasible diagnostic tool based on a cohort of 1,757 patients, of whom 1,284 were diagnosed with COVID-19. This scoring system aimed to diagnose COVID-19 without relying on RT-PCR tests, which often delayed treatment. The scoring required either two or more symptoms, or anosmia or ageusia alone, for individuals without known contact, and one or more symptoms, including anosmia or ageusia alone, for those with known positive contacts. It achieved an accuracy of 80.4% and a sensitivity of 85.7%, surpassing the sensitivity of commercially available RT-PCR tests. The tool was recommended for use to prevent treatment delays, reduce false negatives, and lower diagnostic costs, especially when vaccination rates were insufficient for herd immunity.